235 related articles for article (PubMed ID: 36432116)
1. HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Suk FM; Wu CY; Chiu WC; Chien CY; Chen TL; Liao YJ
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432116
[TBL] [Abstract][Full Text] [Related]
2. β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
Suk FM; Wu CY; Fang CC; Chen TL; Liao YJ
Biomed Pharmacother; 2023 Oct; 166():115293. PubMed ID: 37567069
[TBL] [Abstract][Full Text] [Related]
3. HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma.
Wang YH; Liu CL; Chiu WC; Twu YC; Liao YJ
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31779269
[TBL] [Abstract][Full Text] [Related]
4. HMGCS2 promotes autophagic degradation of the amyloid-β precursor protein through ketone body-mediated mechanisms.
Hu LT; Zhu BL; Lai YJ; Long Y; Zha JS; Hu XT; Zhang JH; Chen GJ
Biochem Biophys Res Commun; 2017 Apr; 486(2):492-498. PubMed ID: 28320515
[TBL] [Abstract][Full Text] [Related]
5. miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma.
Su SG; Yang M; Zhang MF; Peng QZ; Li MY; Liu LP; Bao SY
Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):53-59. PubMed ID: 28867541
[TBL] [Abstract][Full Text] [Related]
6. Fasting-induced HMGCS2 expression in the kidney does not contribute to circulating ketones.
Venable AH; Lee LE; Feola K; Santoyo J; Broomfield T; Huen SC
Am J Physiol Renal Physiol; 2022 Apr; 322(4):F460-F467. PubMed ID: 35224990
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
Hsu CH; Weng PW; Chen MY; Yeh CT; Setiawan SA; Yadav VK; Wu ATH; Tzeng DTW; Gong JX; Yang Z; Tzeng YM
Chem Biol Interact; 2023 Jan; 370():110329. PubMed ID: 36565974
[TBL] [Abstract][Full Text] [Related]
8. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line.
Vilà-Brau A; De Sousa-Coelho AL; Mayordomo C; Haro D; Marrero PF
J Biol Chem; 2011 Jun; 286(23):20423-30. PubMed ID: 21502324
[TBL] [Abstract][Full Text] [Related]
9. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
10. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
11. Sodium butyrate activates HMGCS2 to promote ketone body production through SIRT5-mediated desuccinylation.
Xu Y; Ye X; Zhou Y; Cao X; Peng S; Peng Y; Zhang X; Sun Y; Jiang H; Huang W; Lian H; Yang J; Li J; Ye J
Front Med; 2023 Apr; 17(2):339-351. PubMed ID: 36602721
[TBL] [Abstract][Full Text] [Related]
12. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.
Li J; Li MH; Wang TT; Liu XN; Zhu XT; Dai YZ; Zhai KC; Liu YD; Lin JL; Ge RL; Sun SH; Wang F; Yuan JH
Br J Cancer; 2021 Sep; 125(6):865-876. PubMed ID: 34274945
[TBL] [Abstract][Full Text] [Related]
13. HMGCS2 in metabolic pathways was associated with overall survival in hepatocellular carcinoma: A LASSO-derived study.
Ding R; Chen T; Zhang Y; Chen X; Zhuang L; Yang Z
Sci Prog; 2021; 104(3):368504211031749. PubMed ID: 34260294
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
15. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
16. HMGCS2-Induced Autophagic Degradation of Tau Involves Ketone Body and ANKRD24.
Hu LT; Xie XY; Zhou GF; Wen QX; Song L; Luo B; Deng XJ; Pan QL; Chen GJ
J Alzheimers Dis; 2023; 91(1):407-426. PubMed ID: 36442191
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
18. Ketogenic HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer.
Camarero N; Mascaró C; Mayordomo C; Vilardell F; Haro D; Marrero PF
Mol Cancer Res; 2006 Sep; 4(9):645-53. PubMed ID: 16940161
[TBL] [Abstract][Full Text] [Related]
19. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of hydroxymethylglutaryl CoA synthase reduces ketogenesis and facilitates tumor cell motility in clear cell renal carcinoma.
Han P; Wang Y; Luo W; Lu Y; Zhou X; Yang Y; Zheng Q; Li D; Wu S; Li L; Zhang H; Zhao J; Zhang Z; Matskova L; Li P; Zhou X
Pathol Res Pract; 2021 Nov; 227():153622. PubMed ID: 34624592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
